Global Asthma Treatment Market Report and Forecast 2024-2032

Asthma Treatment Market Outlook

The global asthma treatment market size attained a value of 19.52 billion in 2023. The market is likely to grow further at CAGR of 4.6% during the forecast period of 2024-2032 to reach a value of nearly USD 29.26 billion by 2032, driven by the rising prevalence of asthma triggered by the poor air quality index.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Asthma Treatment Market: Introduction

Asthma is a respiratory disease in which it becomes hard for an individual to breathe due to inflammation in lungs. In this condition, the airways contract and swell, producing excess mucus and resulting in shortness of breath, cough, and wheezing. Asthma happens due to a combination of environmental and genetic factors, or either of the two. Exposure to different irritants and substances like smoke, dust, cold, stress, and certain medications, like aspirin and non-steroidal anti-inflammatory drugs, might light to asthma.

The indication and symptoms of the disease can vary from person to person. An individual may have rare asthma attacks anywhere and at any time. They can experience symptoms while working out or while running and might require immediate help. Asthma symptoms include chest pain, wheezing, shortness of breath, and trouble sleeping due to cough. All these symptoms further worsen the respiratory health.

The diagnosis of asthma depends on the severity of the disease. Based on the symptoms, the doctor may ask for various tests, like allergen tests, skin tests, and imaging tests, to determine the cause of asthma. In case of a severe condition, the doctor may ask for a spirometry test that measures the airflow through the lungs and is used to diagnose and monitor the treatment progress.

Prohibition and long-term control are the only two ways that can prevent asthma attacks to some extent. The treatment procedure for asthma patients also depends on their age and the severity of the symptoms. Long-term asthma drugs are the most relied upon asthma treatment. These drugs keep asthma under control on daily basis, which can reduce the cases of asthma attacks as well. A variety of long-term control drugs include Leukotriene modifiers, Inhaled corticosteroids, Theophylline, and Combination inhalers.

Quick-relief drugs are required for immediate and short-term relief during an asthma attack. A variety of quick-relief medicines include oral and intravenous corticosteroids, Anticholinergic agents, and short-acting beta-agonists. If a person is having an asthma attack, a quick-relief treatment can ease their symptoms immediately, providing relief. But a person should not use a quick-relief inhaler often if the long-term drugs are working correctly, as it might affect the overall treatment.

The cases of asthma treatment are constantly rising as there has been a rapid rise in airborne pollens, triggered by the rising air pollution. Deteriorating climate health and excessive use of antibiotics has significantly contributed to the rising number of asthma patients.

The Centers for Disease Control and Prevention (CDC) published instructions and urged more precautions for asthma patients during the 2019-2020 coronavirus pandemic. This was because asthma patients were more vulnerable to the fatalities of the virus. This triggered the demand for treatment medications to reduce the number of deaths, adding to the growing demand for the medications.

According to the asthma treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis Method

• Physical Exam

• Lung Test
  • Spirometry
  • Peak Flow
• Imaging Test

• Allergy Test

• Nitric Oxide Test

• Others

Market Breakup by Treatment Method

• Long Term Asthma Control Drugs
  • Inhaled Corticosteroids
  • Leukotriene Modifiers
  • Combination Inhalers
  • Theophylline
• Rescue Drugs
  • Short-Acting Beta Agonists
  • Anticholinergic Agents
  • Oral and Intravenous Corticosteroids
• Allergy Drugs
  • Allergy Shots (Immunotherapy)
  • Biologics
  • Bronchial Thermoplasty
• Others

Market Breakup by Type

• Mild Intermittent Asthma

• Mild Persistent Asthma

• Moderate Persistent Asthma

• Severe Persistent Asthma

Market Breakup by Product Type

• Inhalers
  • Dry Powder Inhaler
  • Metered Dose Inhaler
  • Soft Mist Inhaler
• Nebulizer

Market Breakup by Age

• Paediatrics

• Adults

Market Breakup by Distribution Channels

• Hospital Pharmacies

• Retail Pharmacies and Drug Stores

• Online Pharmacies

• Others

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America

• Europe

• The Asia Pacific

• Latin America

• The Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Asthma Treatment Market Scenario

Asthma is prevalent globally because of the rise in tobacco consumption and increase in smoking. These two factors are driving the growth of the asthma treatment market. The increase in air pollution and the prevalence of indoor and outdoor allergens will further add to the number of asthma. The increase in exposure to toxic substances in the laboratory will lead to a rising populace suffering from asthma treatment.

North America is accounting highest incidence of asthma treatment worldwide. The Europe market is witnessing consistent development in the pharma industry and asthma-related therapeutics. Asia Pacific, on the other hand, is estimated to prevail highest growth rate for the estimated period. This leads to increase in global asthma treatment cost market. The awareness about different novel treatments and drugs within the communities will drive the asthma treatment market.

Therapeutic Landscape

Numerous drugs are used to treat asthma disorders, known as asthma therapies. Asthma is triggered by indoor and outdoor factors, such as dust, pollution, and allergens. Bronchodilators and anti-inflammatory medicines, such as immunomodulators, long-acting beta-agonists (LABA), corticosteroids, methylxanthine, and leukotriene modifiers, are commonly used as medication.

The recent scientific investigation has given clinicians the devices for considerably updating the standard of care within the field of bronchial asthma. It implies decreasing steroid-related morbidity, particularly for severe asthma, and most importantly, improving the patient's lifestyle. The recent challenge is to fill the gap between the enormous potential and its execution in day-to-day clinical practice.

Depending upon the symptoms, the following drugs may be prescribed by the physicians based on the diagnosis:

• Short-acting beta-agonists are a quick relief for asthma symptoms, including Albuterol, Epinephrine and Levalbuterol, followed by Anticholinergics, including ipratropium, which lessens mucus to open the airways of the lungs.

• Combination of quick-relief medicines is a mix of both Anticholinergics and Short-acting beta-agonists.

• Long-term drugs are the medications used for long-term relief, reducing swelling and mucus in the airways. It includes inhaled corticosteroids which are the most effective long-term drugs. These drugs are beclomethasone, fluticasone, and mometasone.

• Biologics attack protein or a cell in the body to prevent airway inflammation. It could be a shot or infusion that an asthma patient needs to take every few weeks.

• Leukotriene modifiers relax the muscles around the airways and ease swelling. It can be taken as liquid or pills.

Several combinations treatment drugs are used, which can be taken orally, injected, or inhaled. These medications expand the pathway into the lungs and permit airflow, improving breathing. They help in eliminating mucus from the lungs, which is easy to cough out. One of the primary reasons driving the asthma treatment market growth is the rising prevalence of asthma and other respiratory ailments and advancements in diagnostic technology.

Furthermore, rising public awareness about the availability of effective asthma drugs and treatment is driving the asthma treatment market growth. For example, inhaled corticosteroids are used to treat asthmatic individuals, whereas target-specific medications are used to treat patients with advanced diseases or chronic asthma.

Monoclonal antibodies (mAbs) that inhibit immunoglobulin E and particular cytokines are also in high demand because they are an effective way to treat chronic asthma that is not well treated by other drugs already in the market. Multiple studies have shown that monoclonal antibodies are well tolerated, improve disease control and symptoms, and minimize the requirements for large doses of inhaled corticosteroids.

The key market trends driving the growth include rising healthcare costs, significant research and development (R&D) efforts in healthcare science, and advances in healthcare infrastructure. The annual economic value of asthma was more than a hundred billion dollars, including medical expenditures.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the asthma treatment market are as follows:

• Merck and Co., Inc.

• Sanofi S.A.

• Astellas Pharma Inc.

• Abbott Laboratories

• Novartis International AG

• Pfizer Inc.

• Boehringer Ingelheim International GmbH

• Regeneron Pharmaceuticals, Inc.

• Hoffmann-La Roche Ltd.

• Organon & Co.

• Vectura Group Plc.

• Mundipharma International Ltd.

• GalxoSmithKline Plc.

• Teva Pharmaceuticals Industries Ltd.

Key Highlights of the Report